[HTML][HTML] TMBur: a distributable tumor mutation burden approach for whole genome sequencing
Background Tumor mutation burden (TMB) is a key characteristic used in a tumor-type
agnostic context to inform the use of immune checkpoint inhibitors (ICI). Accurate and …
agnostic context to inform the use of immune checkpoint inhibitors (ICI). Accurate and …
[HTML][HTML] Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms …
DM Merino, LM McShane, D Fabrizio… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …
Tumor mutational burden (TMB) standardization initiative: establishing a consistent methodology for TMB measurement in clinical samples
A Stenzinger, J Allen, J Maas, M Stewart… - Annals of …, 2018 - annalsofoncology.org
Background: Clinical studies have established TMB, a measurement of mutations in the
tumor genome, as a predictive biomarker for clinical efficacy of immune checkpoint inhibitors …
tumor genome, as a predictive biomarker for clinical efficacy of immune checkpoint inhibitors …
[HTML][HTML] Estimating tumor mutational burden across multiple cancer types using whole-exome sequencing
C Zhou, S Chen, F Xu, J Wei, X Zhou, Z Wu… - Annals of …, 2021 - ncbi.nlm.nih.gov
Background Tumor mutational burden (TMB) is emerging as a promising biomarker in
immune checkpoint inhibitor (ICI) therapy. Despite whole-exome sequencing (WES) being …
immune checkpoint inhibitor (ICI) therapy. Despite whole-exome sequencing (WES) being …
[HTML][HTML] Comparison of commonly used solid tumor targeted gene sequencing panels for estimating tumor mutation burden shows analytical and prognostic …
N Bevins, S Sun, Z Gaieb, JA Thorson… - … for immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background Tumor mutation burden (TMB) is a biomarker frequently reported by clinical
laboratories, which is derived by quantifying of the number of single nucleotide or indel …
laboratories, which is derived by quantifying of the number of single nucleotide or indel …
Assessment of tumor mutation burden from> 60,000 clinical cancer patients using comprehensive genomic profiling.
GM Frampton, D Fabrizio, ZR Chalmers, JS Ross… - 2016 - ascopubs.org
11558 Background: Tumor mutation burden (TMB), as measured by whole exome
sequencing, has been shown to strongly correlate with objective responses to immune …
sequencing, has been shown to strongly correlate with objective responses to immune …
Tumor mutational burden standardization initiatives: recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy …
A Stenzinger, JD Allen, J Maas… - Genes …, 2019 - Wiley Online Library
Abstract Characterization of tumors utilizing next‐generation sequencing methods, including
assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently …
assessment of the number of somatic mutations (tumor mutational burden [TMB]), is currently …
[HTML][HTML] Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation'to 'accuracy'
Tumor mutational burden (TMB) assessment is at the forefront in precision medicine. The
TMB could represent a biomarker for immune checkpoint inhibitors (ICIs) responses. Whole …
TMB could represent a biomarker for immune checkpoint inhibitors (ICIs) responses. Whole …
Probabilistic mixture models improve calibration of panel-derived tumor mutational burden in the context of both tumor-normal and tumor-only sequencing
Background: Tumor mutational burden (TMB) has been investigated as a biomarker for
immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene …
immune checkpoint blockade (ICB) therapy. Increasingly, TMB is being estimated with gene …
Harmonizing tumor mutational burden analysis: Insights from a multicenter study using in silico reference data sets in clinical whole-exome sequencing (WES)
L Yu, Y Zhang, D Wang, L Li… - American Journal of …, 2024 - academic.oup.com
Objectives Tumor mutational burden (TMB) is a significant biomarker for predicting immune
checkpoint inhibitor response, but the clinical performance of whole-exome sequencing …
checkpoint inhibitor response, but the clinical performance of whole-exome sequencing …